Biotech companies that saw their stock prices soar on the promise of new drug developments are now facing significant declines following disappointing clinical trial results. After years of research and development, along with investments totaling billions of won, stocks have plummeted by nearly 90% in a short period due to underwhelming outcomes in late-stage trials.
On July 28, the Korea Exchange reported that Kolon TissueGene's stock closed at 14,560 won, down 8.49% from the previous trading day. Following the announcement of the TG-C clinical trial results, the stock has fallen for four consecutive trading days. Notably, it hit the lower limit for three straight days from July 21 to 23, and then dropped another 28.74% on July 24. Compared to its peak of 149,000 won on May 12, the stock has lost about 90% of its value in just over two months.
Stock prices in the biotech sector are highly sensitive to expectations at various clinical trial stages. Positive results in Phase 1 and 2 trials or heightened expectations for technology transfers can lead to rapid increases in company valuations. However, when disappointing results emerge in the critical Phase 3 trials, companies often see most of their gains wiped out.
Industry experts have reiterated that entering late-stage clinical trials does not guarantee success. Kolon TissueGene's TG-C showed pain relief and improved joint function in its first Phase 3 trial, but it failed to meet the statistical significance required for the primary endpoint, a key criterion for approval. The company is currently analyzing the unexpectedly high placebo response and awaiting results from a second independent trial.
Samchundang Pharm is another example of a company that has seen its stock price collapse as expectations for new drugs have rapidly diminished. The company's stock soared to 1,233,000 won on March 30, driven by optimism surrounding obesity treatments. However, ongoing uncertainties regarding development timelines and clinical trials have led to a steady decline, with the stock closing at 139,500 won, marking an approximately 89% drop from its peak in just four months.
An industry insider noted, "In biotech, a company's value can fluctuate significantly based on the success of new drug development, so relying solely on expectations can lead to substantial volatility. Investors need to assess the clinical progress, data quality, potential for technology transfer, and whether it can translate into actual sales."
Financial authorities are also taking steps to protect investors in biotech stocks. The Financial Supervisory Service has established a task force aimed at improving disclosures in the pharmaceutical and biotech sectors and is expected to announce measures to enhance investor protection soon.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.